Imatinib was originally developed as an inhibitor for the oncogene BCR-ABL tyrosine kinase, and it is an approved drug for chronic myelogenous leukemia (47). Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.